The addition of either LAG3, TIGIT, or IL-27 inhibition to the anti PD(L)1 + anti-VEGF doublet shares a common rationale: all these targets were demonstrated to exert an immune-suppressive effect on TME, thus their inhibition should lead to immunogenicity restoration in HCC. The gene discussed is LAG3; the disease is hepatocellular carcinoma.